Review article: Infliximab for Crohn's disease treatment - Shifting therapeutic strategies after 10 years of clinical experience

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 8, 2011, Pages 857-869

  Danese, S ^a   Colombel, J F ^b   Reinisch, W ^c   Rutgeerts, P J ^d  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ANUS FISTULA; CATARACT; CLINICAL TRIAL (TOPIC); CORTICOSTEROID INDUCED OSTEOPOROSIS; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; IMMUNOMODULATION; INFECTION; LATENT TUBERCULOSIS; MAINTENANCE THERAPY; OPPORTUNISTIC INFECTION; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REMISSION; REVIEW; RISK FACTOR; SIDE EFFECT; VACCINATION; WEIGHT GAIN;

EID: 79952795096     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04598.x     Document Type: Review

References (62)

1. Sachar DB, Andrew HA, Farmer RG, et al. Proposed classification of patient subgroups in Crohn's disease. Gastroenterol Intern 1992; 5: 141-54.
2. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50. (Pubitemid 34784976)
3. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-8. (Pubitemid 350181602)
4. Munkholm P, Langholz E, Davidsen M, Binder V,. Disease activity courses in a regional cohort of Crohn's. Scand J Gastroenterol 1995; 30: 699-706.
5. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13. (Pubitemid 38182297)
6. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome for maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15: 1295-301.
7. Solberg IC, Lygren I, Jahnsen J, et al. Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease. Gut 2008; 57 (Suppl. II): A-15.
8. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: when to Start, When to Stop, Which Drug to Choose, and How to Predict Response? Am J Gastroenterol 2011; 106: 199-212.
9. Travis SP, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 (Suppl. 1): i16-35. (Pubitemid 43268291)
10. Lichtenstein GR, Hanauer SB, Sandborn WJ,. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-83.
11. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W,. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 940-87. (Pubitemid 43374543)
12. Remicade® (infliximab) Summary of Product Characteristics (SPC). Leiden, The Netherlands: Centocor BV, 2010.
13. Humira® (adalimumab) Summary of Product Characteristics (SPC). Berkshire, UK: Abbott Labratories Limited, 2010.
14. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
15. Lèmann M, Mary J-Y, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomised, placebo-controlled trial. Gastroenterology 2006; 130: 1054-61.
16. Colombel J-F, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
17. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7. (Pubitemid 351284485)
18. Hyams J, Crandall W, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73. (Pubitemid 46454266)
19. Feagan BG, McDonald J, Ponich T, et al. A randomized trial of methotrexate (MTX) in combination with infliximab (IFX) for the treatment of Crohn's disease (CD) [late-breaking abstract]. Gastroenterology 2008; 134 (Suppl. 1): 682c.
20. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
21. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
22. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-9.
23. Rutgeerts P, D'Haens G, van Assche G, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease-first results of the EXTEND Trial. Gastroenterology 2009; 136 (Suppl. 1): A-116.
24. Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 674-88.
25. Steinhart AH,. Induction therapy in Crohn's disease. In:, Williams CN, Bursey RF, Gall DG, Martin F, McLeod RS, Sutherland LR, Wallace JL, eds. Trends in Inflammatory Bowel Disease Therapy 1999. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2000: 128-36.
26. Yun L, Hanauer S,. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2009; 3: 235-48.
27. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010; 4: 28-62.
28. Chilton F, Collett RA,. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 2008; 6: 1-14.
29. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-6. (Pubitemid 43374514)
30. Franchimont D, Louis E, Croes F, Belaiche F,. Clinical pattern of corticosteroid dependent Crohn's disease. Eur J Gastroenterol Hepatol 1998; 10: 821-5. (Pubitemid 28493255)
31. Loly C, Belaiche J, Louis E,. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-54.
32. Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn's disease: a 35-year follow up study of 507 patients. Gastroenterology 1998; 114: 1151-60. (Pubitemid 28243900)
33. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-9. (Pubitemid 40523539)
34. Sandborn WJ, Fazio VW, Feagan BG, et al. American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125: 1508-30.
35. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85. (Pubitemid 38252535)
36. Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006; 101: 1030-8. (Pubitemid 43725317)
37. Munkholm P, Langholz E, Davidsen M, Binder V,. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105: 1716-23. (Pubitemid 24002788)
38. Eshuis EJ, Bemelman WA, van Bodegraven AA, et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). BMC Surg 2008; 8: 15.
39. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
40. Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80-5.
41. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-8. (Pubitemid 351790744)
42. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-26.
43. Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363-8.
44. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F,. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
45. Data on file. Centocor, Inc.
46. Gisbert JP, Panés J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
47. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
48. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38. (Pubitemid 351650483)
49. Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010; 31: 92-101.
50. Domènech E, Hinojosa J, Nos P, et al. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther 2005; 22: 1107-13. (Pubitemid 41779518)
51. Louis E, Vernier-Massouille G, Grimaud J, et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut 2008; 57: A66.
52. Louis E, Vernier-Massouille G, Grimaud J, et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 2009; 136: A-146.
53. Hyder SA, Travis SPL, Jewell DP, et al. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006; 49: 1837-41. (Pubitemid 44853440)
54. Tougeron D, Savoye G, Savoye-Collet C, et al. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease. Dig Dis Sci 2009; 54: 1746-52.
55. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies or Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
56. Sutherland LR, Ramcharan S, Bryant H, Fick G,. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98: 1123-8. (Pubitemid 20143093)
57. Lindberg E, Järnerot G, Huitfeldt B,. Smoking in Crohn's disease: effect on localisation and clinical course. Gut 1992; 33: 779-82.
58. Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006; 101: 2410-22. (Pubitemid 44477569)
59. Gearry RB, Roberts RL, Burt MJ, et al. Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflamm Bowel Dis 2007; 13: 1220-7. (Pubitemid 47597768)
60. Armuzzi A, Amah T, Ling KL, et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 2003; 52: 1133-9. (Pubitemid 36877425)
61. Boirivant M, Leoni M, Tariciotti D, Fais S, Squarcia O, Pallone F,. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988; 10: 401-5.
62. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R,. Term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97: 947-53. (Pubitemid 34408253)